Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to ...

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.

Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...

Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.

Johnson & Johnson MedTech announced that it has temporarily paused the United States External Evaluation and all United Stat ...

Qure.ai announced today that it appointed Jim Mercadante, a 25-year medtech veteran, as its new chief commercial officer (CCO ...

We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile ...

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...